Literature DB >> 1356518

International Conference on Growth Control in Breast Cancer: Basic and Clinical Aspects. Taormina, Italy, December 13-14, 1991. Abstracts.

.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1356518

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


× No keyword cloud information.
  7 in total

1.  Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding.

Authors:  A Migliaccio; M Di Domenico; S Green; A de Falco; E L Kajtaniak; F Blasi; P Chambon; F Auricchio
Journal:  Mol Endocrinol       Date:  1989-07

2.  Inactivation of oestrogen receptor in vitro by nuclear dephosphorylation.

Authors:  F Auricchio; A Migliaccio; A Rotondi
Journal:  Biochem J       Date:  1981-02-15       Impact factor: 3.857

3.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype.

Authors:  F Giorgino; A Belfiore; G Milazzo; A Costantino; B Maddux; J Whittaker; I D Goldfine; R Vigneri
Journal:  Mol Endocrinol       Date:  1991-03

5.  Sex hormone receptors in mammary tumours of GR mice.

Authors:  M Sluyser; S G Evers; C C De Goeij
Journal:  Nature       Date:  1976-09-30       Impact factor: 49.962

6.  Calmodulin-stimulated phosphorylation of 17 beta-estradiol receptor on tyrosine.

Authors:  A Migliaccio; A Rotondi; F Auricchio
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

7.  Estradiol receptor: phosphorylation on tyrosine in uterus and interaction with anti-phosphotyrosine antibody.

Authors:  A Migliaccio; A Rotondi; F Auricchio
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.